Cadus Buys $2m Axiom Preferred Stock

8 June 1997

- Cadus Pharmaceutical has purchased $2 million of AxiomBiotechnologies' preferred stock, and 26% of outstanding shares. It may acquire an additional $2 million shares of preferred stock. In return, Axiom will license to Cadus its High Throughput Pharmacological Screening system. The ability to automate pharmaceutical screening in human cells through Axiom's technology should enable Cadus to accelerate drug discovery, commented a spokesperson for Cadus.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight